Fresenius SE & Co KGaA’s (FRE) Buy Rating Reiterated at DZ Bank

DZ Bank reaffirmed their buy rating on shares of Fresenius SE & Co KGaA (FRA:FRE) in a report issued on Thursday.

Several other equities analysts have also commented on the stock. HSBC set a €68.00 ($83.95) price target on shares of Fresenius SE & Co KGaA and gave the stock a neutral rating in a research report on Monday, March 26th. Barclays set a €81.00 ($100.00) price target on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Friday, March 9th. Berenberg Bank set a €89.10 ($110.00) price target on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Tuesday, March 6th. Societe Generale set a €85.00 ($104.94) price target on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Monday, March 5th. Finally, Cfra set a €76.00 ($93.83) price target on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Thursday, March 1st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have issued a buy rating to the company. Fresenius SE & Co KGaA has a consensus rating of Buy and an average price target of €77.74 ($95.98).

How to Become a New Pot Stock Millionaire

Shares of FRE stock opened at €63.38 ($78.25) on Thursday. Fresenius SE & Co KGaA has a one year low of €60.16 ($74.27) and a one year high of €80.00 ($98.77).

ILLEGAL ACTIVITY WARNING: “Fresenius SE & Co KGaA’s (FRE) Buy Rating Reiterated at DZ Bank” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/3339874/fresenius-se-co-kgaas-fre-buy-rating-reiterated-at-dz-bank.html.

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Verona Pharma  Receives Average Rating of “Buy” from Analysts
Verona Pharma Receives Average Rating of “Buy” from Analysts
Brokerages Set Protagonist Therapeutics Inc  PT at $25.00
Brokerages Set Protagonist Therapeutics Inc PT at $25.00
Arcos Dorados Holdings  Given Consensus Rating of “Buy” by Brokerages
Arcos Dorados Holdings Given Consensus Rating of “Buy” by Brokerages
Vulcano  Hits Market Capitalization of $0.00
Vulcano Hits Market Capitalization of $0.00
Digital Bullion Gold 24 Hour Trading Volume Reaches $17.00
Digital Bullion Gold 24 Hour Trading Volume Reaches $17.00
Somewhat Positive Media Coverage Somewhat Unlikely to Impact Xcel Energy  Share Price
Somewhat Positive Media Coverage Somewhat Unlikely to Impact Xcel Energy Share Price


Leave a Reply

© 2006-2018 Ticker Report. Google+.